Company Encyclopedia
View More
name
Aspire Biopharma
ASBP.US
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement.
4.359 T
ASBP.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Aspire Biopharma Enters New $100M ELOC Agreement

    Aspire Biopharma Holdings has entered a new $100M Equity Line of Credit Agreement with Arena Business Solutions Global SPC II, Ltd., providing financial flexibility and potential capital for future operations. The previous ELOC Agreement has been terminated, marking a strategic shift in financial arrangements.

    Tip Ranks·
    US
    ASBP
    +15.02%
    Tip Ranks·
    US
    ASBP
    +15.02%

    Aspire Biopharma | 10-Q: FY2025 Q3 Revenue: USD 1.941 K

    LB filings·
    US
    ASBP
    +15.02%
    LB filings·
    US
    ASBP
    +15.02%

    Aspire Biopharma Holdings, Inc. SEC 10-Q Report

    Aspire Biopharma Holdings, Inc. released its Form 10-Q report for Q3, highlighting minimal revenue of $1,941 and a significant net loss of $19,773,114. The company focuses on sublingual delivery mechanisms for drugs and supplements, with most sales in the USA. Future plans include expanding sales, marketing, and R&D, requiring additional financing.

    TradingView·
    US
    ASBP
    +15.02%
    TradingView·
    US
    ASBP
    +15.02%

    Aspire Biopharma Holdings Inc. reports net revenue of $1,941 for Q3 2025

    Aspire Biopharma Holdings Inc. reported a net revenue of $1,941 for Q3 2025, marking an increase from zero revenue in the same period of 2024. The company, an early-stage biopharmaceutical and supplements firm, completed a reverse acquisition, identifying Aspire Biopharma, Inc. as the accounting acquirer. This led to non-competition and lock-up agreements with certain officers, directors, and stockholders. The company's quarterly report includes discussions on accounting standards and policies.

    Reuters·
    US
    ASBP
    +15.02%
    Reuters·
    US
    ASBP
    +15.02%

    Aspire Biopharma Announces $100 Million Unregistered Share Sale Under Equity Line Agreement

    Aspire Biopharma Holdings Inc. has entered into an Equity Line of Credit Agreement with Arena Business Solutions Global SPC II, Ltd., allowing the sale of up to $100 million in common stock over 36 months. The shares will be issued under exemptions from registration as Arena is an accredited investor. The sale is subject to certain terms, including a registration statement for resale. This information was published via EDGAR on November 14, 2025.

    Reuters·
    US
    ASBP
    +15.02%
    Reuters·
    US
    ASBP
    +15.02%